Relmada Therapeutics (RLMD) Competitors $0.65 -0.02 (-2.78%) Closing price 04:00 PM EasternExtended Trading$0.67 +0.02 (+3.29%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. IGMS, VRCA, ANRO, MGX, VTGN, ADAP, OTLK, SRZN, CELU, and PYXSShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include IGM Biosciences (IGMS), Verrica Pharmaceuticals (VRCA), Alto Neuroscience (ANRO), Metagenomi (MGX), VistaGen Therapeutics (VTGN), Adaptimmune Therapeutics (ADAP), Oncobiologics (OTLK), Surrozen (SRZN), Celularity (CELU), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors IGM Biosciences Verrica Pharmaceuticals Alto Neuroscience Metagenomi VistaGen Therapeutics Adaptimmune Therapeutics Oncobiologics Surrozen Celularity Pyxis Oncology IGM Biosciences (NASDAQ:IGMS) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Do analysts prefer IGMS or RLMD? IGM Biosciences currently has a consensus price target of $5.50, indicating a potential upside of 333.07%. Relmada Therapeutics has a consensus price target of $5.00, indicating a potential upside of 673.16%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media refer more to IGMS or RLMD? In the previous week, IGM Biosciences had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for IGM Biosciences and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.89 beat IGM Biosciences' score of 1.07 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment IGM Biosciences Positive Relmada Therapeutics Very Positive Which has more volatility and risk, IGMS or RLMD? IGM Biosciences has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Is IGMS or RLMD more profitable? Relmada Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Relmada Therapeutics' return on equity of -181.26% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,417.79% -317.97% -71.43% Relmada Therapeutics N/A -181.26%-151.23% Do institutionals and insiders believe in IGMS or RLMD? 42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, IGMS or RLMD? Relmada Therapeutics has lower revenue, but higher earnings than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.68M28.33-$195.79M-$3.27-0.39Relmada TherapeuticsN/AN/A-$79.98M-$2.51-0.26 SummaryRelmada Therapeutics beats IGM Biosciences on 11 of the 15 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.46M$2.82B$5.74B$9.51BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-0.269.0428.1120.03Price / SalesN/A744.02461.37103.88Price / CashN/A166.2336.5559.01Price / Book0.555.168.655.90Net Income-$79.98M$30.99M$3.25B$258.66M7 Day Performance12.08%7.74%4.20%2.23%1 Month Performance19.76%16.18%10.82%12.76%1 Year Performance-84.03%-1.03%34.70%19.36% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.8118 of 5 stars$0.65-2.8%$5.00+673.2%-83.6%$21.46MN/A-0.2610Positive NewsGap DownIGMSIGM Biosciences4.53 of 5 stars$1.28flat$5.50+329.7%-89.6%$76.51M$2.68M-0.39190Positive NewsVRCAVerrica Pharmaceuticals4.1329 of 5 stars$0.77-5.8%$8.00+940.2%-90.2%$75.50M$7.57M-0.6440Positive NewsGap DownANROAlto Neuroscience2.4036 of 5 stars$2.74-1.5%$8.50+210.3%-79.4%$75.26MN/A-1.17N/ATrending NewsMGXMetagenomi3.2232 of 5 stars$2.17+9.0%$13.00+499.1%-45.8%$74.39M$52.29M-1.03236Gap UpVTGNVistaGen Therapeutics0.4606 of 5 stars$2.55flatN/A-26.4%$74.35M$490K-1.5440News CoverageHigh Trading VolumeADAPAdaptimmune Therapeutics1.9629 of 5 stars$0.28-1.1%$1.35+388.8%-73.0%$74.08M$178.03M-1.02490News CoverageOTLKOncobiologics2.258 of 5 stars$2.06-5.5%$9.60+366.0%-75.5%$73.18MN/A-2.2620News CoverageSRZNSurrozen2.7641 of 5 stars$8.70+2.6%$38.50+342.5%+5.3%$72.61M$10.65M-0.3580Positive NewsHigh Trading VolumeCELUCelularity0.1416 of 5 stars$3.15+4.0%N/A+3.6%$72.57M$54.22M-1.19220News CoverageUpcoming EarningsPYXSPyxis Oncology2.4157 of 5 stars$1.13flat$9.00+696.5%-64.5%$70M$16.15M-0.7160 Related Companies and Tools Related Companies IGM Biosciences Alternatives Verrica Pharmaceuticals Alternatives Alto Neuroscience Alternatives Metagenomi Alternatives VistaGen Therapeutics Alternatives Adaptimmune Therapeutics Alternatives Oncobiologics Alternatives Surrozen Alternatives Celularity Alternatives Pyxis Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts